[go: up one dir, main page]

WO2006071603A3 - Phosphodiesterase 4d in the ryanodine receptor complex protects against heart failure - Google Patents

Phosphodiesterase 4d in the ryanodine receptor complex protects against heart failure Download PDF

Info

Publication number
WO2006071603A3
WO2006071603A3 PCT/US2005/045914 US2005045914W WO2006071603A3 WO 2006071603 A3 WO2006071603 A3 WO 2006071603A3 US 2005045914 W US2005045914 W US 2005045914W WO 2006071603 A3 WO2006071603 A3 WO 2006071603A3
Authority
WO
WIPO (PCT)
Prior art keywords
ryanodine receptor
disorders
present
diseases
phosphodiesterase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/045914
Other languages
French (fr)
Other versions
WO2006071603A9 (en
WO2006071603A2 (en
Inventor
Andrew R Marks
Stephan E Lehnart
Xander H T Wehrens
Steven Reiken
Marco Conti
Catherine S L Jin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Priority to CA002591924A priority Critical patent/CA2591924A1/en
Publication of WO2006071603A2 publication Critical patent/WO2006071603A2/en
Publication of WO2006071603A3 publication Critical patent/WO2006071603A3/en
Publication of WO2006071603A9 publication Critical patent/WO2006071603A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04053—3',5'-Cyclic-AMP phosphodiesterase (3.1.4.53)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides compositions useful for treating and preventing ryanodine receptor associated disorders comprising a PDE-associated agent and a pharmaceutically acceptable carrier. The present invention also provides methods for treating or preventing ryanodine receptor associated disorders including cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases malignant hyperthermia, diabetes and sudden infant death syndrome. The present invention further provides methods for regulating PKA phosphorylation of a ryanodine receptor as well as methods for regulating Ca+2 release and reuptake in cells. Also provided are kits for use in delivering a PDE-associated agent to cardiac cells in a subject, comprising the composition of the present invention and a catheter.
PCT/US2005/045914 2004-12-16 2005-12-15 Phosphodiesterase 4d in the ryanodine receptor complex protects against heart failure Ceased WO2006071603A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002591924A CA2591924A1 (en) 2004-12-16 2005-12-15 Phosphodiesterase 4d in the ryanodine receptor complex protects against heart failure

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63695904P 2004-12-16 2004-12-16
US60/636,959 2004-12-16

Publications (3)

Publication Number Publication Date
WO2006071603A2 WO2006071603A2 (en) 2006-07-06
WO2006071603A3 true WO2006071603A3 (en) 2006-10-12
WO2006071603A9 WO2006071603A9 (en) 2007-03-29

Family

ID=36615403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/045914 Ceased WO2006071603A2 (en) 2004-12-16 2005-12-15 Phosphodiesterase 4d in the ryanodine receptor complex protects against heart failure

Country Status (2)

Country Link
CA (1) CA2591924A1 (en)
WO (1) WO2006071603A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
AU2004220548A1 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054531A1 (en) * 2001-03-19 2003-03-20 Decode Genetics Ehf, Human stroke gene
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
WO2004042389A2 (en) * 2002-11-08 2004-05-21 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
EP1439221A1 (en) * 2002-12-17 2004-07-21 F. Hoffmann-La Roche Ag PDE core construct
US20040224368A1 (en) * 2003-03-07 2004-11-11 Marks Andrew R. Type 1 ryanodine receptor-based methods

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US20030054531A1 (en) * 2001-03-19 2003-03-20 Decode Genetics Ehf, Human stroke gene
WO2004042389A2 (en) * 2002-11-08 2004-05-21 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
EP1439221A1 (en) * 2002-12-17 2004-07-21 F. Hoffmann-La Roche Ag PDE core construct
US20040224368A1 (en) * 2003-03-07 2004-11-11 Marks Andrew R. Type 1 ryanodine receptor-based methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAPILOFF MICHAEL S; JACKSON NICOLE; AIRHART NATHAN: "mAKAP and the ryanodine receptor are part of a multi-component signaling complex on the cardiomyocyte nuclear envelope", JOURNAL OF CELL SCIENCE, vol. 114, no. 17, September 2001 (2001-09-01), pages 3167 - 3176, XP002390984 *
LEHNART STEPHAN E; WEHRENS XANDER H; REIKEN STEVEN R; JIN S -I C; VEST JOHN A; MARKS ANDREW R: "Phosphodiesterase 4D associates with the cardiac calcium release channel (Ryanodine receptor) and protects from hypertrophy and heart failure", CIRCULATION, vol. 110, no. 17SupplS, 26 October 2004 (2004-10-26), pages 227 - 228, XP009069565 *

Also Published As

Publication number Publication date
WO2006071603A9 (en) 2007-03-29
WO2006071603A2 (en) 2006-07-06
CA2591924A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
MX2007004882A (en) Xanthine derivatives with hm74a receptor activity.
HRP20130406T1 (en) Medicaments with hm74a receptor activity
ES2974972T3 (en) Heterocyclic flavone derivatives, compositions and methods related thereto
WO2006071778A3 (en) Treatment of parkinson's disease and related disorders using postpartum derived cells
TN2009000137A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2009082459A3 (en) Anti-aging composition containing resveratrol and method of administration
YU96502A (en) Benzothiazole derivatives
WO2009106991A3 (en) Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
GB0421639D0 (en) Methods and compositions relating to alzheimer's disease
WO2005067546A3 (en) Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
EP2512479A4 (en) Methods and compositions for treating peripheral vascular disease
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
WO2006070325A3 (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
MX2011010732A (en) Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease.
NO20082872L (en) Purine derivatives and processes for their use
JP2017526695A5 (en)
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
WO2006071603A3 (en) Phosphodiesterase 4d in the ryanodine receptor complex protects against heart failure
WO2005009217A3 (en) Diagnosis of pre-cancerous conditions using pcdgf agents
WO2014107685A2 (en) Compositions and methods for using huperzine and analogs thereof
SG140605A1 (en) Benzothiazole derivatives
TW200501946A (en) Pharmaceutical composition for the treatment of schizophrenia in a patient with overweight

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2591924

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007546999

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 05857129

Country of ref document: EP

Kind code of ref document: A2